The ABCs of antiphospholipid syndrome

被引：6

作者：

Dincer, Ayse Bahar Kelesoglu ^{[1
,2
]}

Erkan, Doruk ^{[3
,4
]}

机构：

[1] Diskapi Yildirim Beyazit Training & Res Hosp, Div Rheumatol, Ankara, Turkiye

[2] Hosp Special Surg, New York, NY USA

[3] Hosp Special Surg, Barbara Volcker Ctr Women & Rheumat Dis, New York, NY 10021 USA

[4] Weill Cornell Med, New York, NY 10021 USA

来源：

ARCHIVES OF RHEUMATOLOGY | 2023年 / 38卷 / 02期

关键词：

Antiphospholipid antibody; antiphospholipid syndrome; thrombosis; INTERNATIONAL CONSENSUS STATEMENT; PRIMARY THROMBOSIS PREVENTION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTOIMMUNE HEMOLYTIC-ANEMIA; CLASSIFICATION CRITERIA; RECURRENT THROMBOSIS; ANTIBODIES; TRIAL; MANIFESTATIONS; INHIBITION;

D O I：

10.46497/ArchRheumatol.2023.41875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by thrombotic, microvascular, obstetric, or non -thrombotic events in the setting of persistent antiphospholipid antibodies (aPL), namely anticardiolipin antibody (aCL), anti -132 glycoprotein-I antibody (a132GPI), and lupus anticoagulant (LA). The diagnosis of APS requires careful assessment of the aPL profile, the clinical phenotype, and additional risk factors. The standard management of aPL-related thrombosis is anticoagulation, which is not effective for microvascular and non -thrombotic events. In parallel to our improved understanding of aPL-related mechanisms, the role of immunosuppression has been increasingly investigated. In this review, we summarize the basic concepts and future perspectives in APS.

引用

页码：163 / 173

页数：11

共 60 条

[1]

Agmon-Levin N, 2021, CLIN EXP RHEUMATOL, V39, P1049, DOI 10.55563/clinexprheumatol/cc5taf

[2] Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome [J].